Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720762 | 0.99 | MCHR1 (0.40) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2720511 | 0.99 | MCHR1 (0.40) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2717750 | 0.99 | MCHR1 (0.40) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2718476 | 0.96 | MCHR1 (0.41) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2720700 | 0.87 | HRH3 (0.48) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2721209 | 0.86 | HRH3 (0.47) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2718716 | 0.86 | HRH3 (0.47) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2719849 | 0.86 | HRH3 (0.47) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2830276 | 0.84 | MCHR1 (0.40) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2719918 | 0.84 | MCHR1 (0.45) | MCHR1HRH3KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1995245-B1 | METHOD FOR PRODUCING EPOXY COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20100160555-A1 | RESIN COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2133380-A1 | RESIN COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090054669-A1 | Process For Producing Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LTD. | 2009-01-15 | — | — | US | disclosed |
| EP-1995245-A1 | METHOD FOR PRODUCING EPOXY COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995244-A1 | METHOD FOR CRYSTALLIZATION OF EPOXY COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | PTGER1, NR5A1, TCP1 | MCHR1 1198/4885HRH3 2077/4885KCNH2 2482/4885 |
| US-20090054669-A1 | Process For Producing Epoxy Compound | RER1, AR, CYP1A1 | MCHR1 621/4885HRH3 19/4885KCNH2 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.